Am J Perinatol 2014; 31(11): 1003-1008
DOI: 10.1055/s-0034-1370347
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Higher-Dose Oxytocin to Prevent Obstetric Hemorrhage at Vaginal Delivery—Does Duration of Infusion Matter?

Akila Subramaniam
1  Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
,
Adi R. Abramovici
1  Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
,
Jeffery M. Szychowski
2  Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama
,
Michelle Roach
1  Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
,
John Owen
1  Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
,
Joseph R. Biggio
1  Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
,
Alan T. N. Tita
1  Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
› Author Affiliations
Further Information

Publication History

01 December 2013

26 December 2013

Publication Date:
28 February 2014 (online)

Abstract

Objective Postpartum higher-dose oxytocin (80 U) compared with lower dose (10 U) given in 500 mL over 1 hour does not decrease postpartum hemorrhage (PPH) requiring treatment, but reduces the risk of hematocrit decline ≥ 6% among women delivering vaginally. Our objective was to evaluate whether the duration of administration of oxytocin influences outcomes.

Study Design We compared a cohort receiving a postpartum oxytocin infusion of 80 U/500 mL over 1 hour to a concurrent cohort of women receiving 80 U/500 mL over 8 hours. The primary outcome was any treatment of PPH (uterotonics, blood transfusion, tamponade, and surgery). Secondary outcomes included pre- to postdelivery median hematocrit change and hematocrit decline ≥ 6%.

Results There were 653 and 676 women identified in the 1- and 8-hour cohorts, respectively. There was no difference in PPH requiring any treatment between the 1- and 8-hour cohorts (6 vs. 6%, p = 0.70). There were no differences in individual treatment components including blood transfusion (p = 0.75). Median hematocrit decline (p = 0.02) was lower in the 8-hour cohort, but there was no difference in frequency of hematocrit decline ≥ 6% (p = 0.15). Results were unchanged by multivariable adjustments.

Conclusions Postpartum higher-dose oxytocin administered over 1 hour compared with 8 hours was not associated with an increased treatment of PPH or frequency of hematocrit decline ≥ 6%.

Note

This study was presented at the 61st Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists in New Orleans, LA, May 4 to 8, 2013.